🟢 Health ETF (ARKG) is trading 4.1% up in pre-market after positive Moderna-Merck melanoma-vaccine results

ARKG is trading at $44.98, up +4.09% pre-market after positive late-stage melanoma-vaccine results from Moderna and Merck.

• Combination therapy met key goals for reducing melanoma recurrence and distant spread in a trial of more than 1,100 patients.
• Healthcare is outperforming pre-market as Moderna rose sharply and Merck gained about 8%, lifting vaccine and biotech shares.
• Broader futures are firmer and Treasury yields eased modestly ahead of the 2:00 p.m. FOMC minutes release; macro factors are supportive but secondary.